Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies

Antimalarial chemotherapy relies on combination therapies (ACTs) consisting of an artemisinin derivative and a partner drug. Here, the authors study the effects of globally prevalent mutations in a multidrug resistance transporter (PfMDR1) on the parasite’s susceptibility to ACT drugs.

Guardado en:

Detalles Bibliográficos
Autores principales:	M. Isabel Veiga, Satish K. Dhingra, Philipp P. Henrich, Judith Straimer, Nina Gnädig, Anne-Catrin Uhlemann, Rowena E. Martin, Adele M. Lehane, David A. Fidock
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2016
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/dbb046e77b4e470caabc3ad9b066a983
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dbb046e77b4e470caabc3ad9b066a983
record_format	dspace
spelling	oai:doaj.org-article:dbb046e77b4e470caabc3ad9b066a9832021-12-02T14:39:15ZGlobally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies10.1038/ncomms115532041-1723https://doaj.org/article/dbb046e77b4e470caabc3ad9b066a9832016-05-01T00:00:00Zhttps://doi.org/10.1038/ncomms11553https://doaj.org/toc/2041-1723Antimalarial chemotherapy relies on combination therapies (ACTs) consisting of an artemisinin derivative and a partner drug. Here, the authors study the effects of globally prevalent mutations in a multidrug resistance transporter (PfMDR1) on the parasite’s susceptibility to ACT drugs.M. Isabel VeigaSatish K. DhingraPhilipp P. HenrichJudith StraimerNina GnädigAnne-Catrin UhlemannRowena E. MartinAdele M. LehaneDavid A. FidockNature PortfolioarticleScienceQENNature Communications, Vol 7, Iss 1, Pp 1-12 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q M. Isabel Veiga Satish K. Dhingra Philipp P. Henrich Judith Straimer Nina Gnädig Anne-Catrin Uhlemann Rowena E. Martin Adele M. Lehane David A. Fidock Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies
description	Antimalarial chemotherapy relies on combination therapies (ACTs) consisting of an artemisinin derivative and a partner drug. Here, the authors study the effects of globally prevalent mutations in a multidrug resistance transporter (PfMDR1) on the parasite’s susceptibility to ACT drugs.
format	article
author	M. Isabel Veiga Satish K. Dhingra Philipp P. Henrich Judith Straimer Nina Gnädig Anne-Catrin Uhlemann Rowena E. Martin Adele M. Lehane David A. Fidock
author_facet	M. Isabel Veiga Satish K. Dhingra Philipp P. Henrich Judith Straimer Nina Gnädig Anne-Catrin Uhlemann Rowena E. Martin Adele M. Lehane David A. Fidock
author_sort	M. Isabel Veiga
title	Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies
title_short	Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies
title_full	Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies
title_fullStr	Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies
title_full_unstemmed	Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies
title_sort	globally prevalent pfmdr1 mutations modulate plasmodium falciparum susceptibility to artemisinin-based combination therapies
publisher	Nature Portfolio
publishDate	2016
url	https://doaj.org/article/dbb046e77b4e470caabc3ad9b066a983
work_keys_str_mv	AT misabelveiga globallyprevalentpfmdr1mutationsmodulateplasmodiumfalciparumsusceptibilitytoartemisininbasedcombinationtherapies AT satishkdhingra globallyprevalentpfmdr1mutationsmodulateplasmodiumfalciparumsusceptibilitytoartemisininbasedcombinationtherapies AT philippphenrich globallyprevalentpfmdr1mutationsmodulateplasmodiumfalciparumsusceptibilitytoartemisininbasedcombinationtherapies AT judithstraimer globallyprevalentpfmdr1mutationsmodulateplasmodiumfalciparumsusceptibilitytoartemisininbasedcombinationtherapies AT ninagnadig globallyprevalentpfmdr1mutationsmodulateplasmodiumfalciparumsusceptibilitytoartemisininbasedcombinationtherapies AT annecatrinuhlemann globallyprevalentpfmdr1mutationsmodulateplasmodiumfalciparumsusceptibilitytoartemisininbasedcombinationtherapies AT rowenaemartin globallyprevalentpfmdr1mutationsmodulateplasmodiumfalciparumsusceptibilitytoartemisininbasedcombinationtherapies AT adelemlehane globallyprevalentpfmdr1mutationsmodulateplasmodiumfalciparumsusceptibilitytoartemisininbasedcombinationtherapies AT davidafidock globallyprevalentpfmdr1mutationsmodulateplasmodiumfalciparumsusceptibilitytoartemisininbasedcombinationtherapies
_version_	1718390684197584896

Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies

Ejemplares similares